Instil Bio, Inc.

NasdaqCM TIL

Instil Bio, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 60.51%

Instil Bio, Inc. Gross Profit Margin is 60.51% for the Trailing 12 Months (TTM) ending September 30, 2024. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqCM: TIL

Instil Bio, Inc.

CEO	Mr. Bronson Crouch
IPO Date	March 19, 2021
Location	United States
Headquarters	3963 Maple Avenue
Employees	49
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

Key trends

Past 5 years